members only »

About us

The SSG was formed in 1979 by physicians and scientists from the Scandinavian countries with a primary interest in tumors of connective tissues.

The goal of the SSG is to advance the care of patients with sarcoma and to increase knowledge of all aspects of the biology of these tumors, including basic and clinical research. The SSG has developed treatment protocols for different sarcoma types and participates in international clinical trials.

At this SSG web-site you can access treatment protocols, find information about previous and future SSG meetings with links to SSG publications.

SSG secretary: Eva-Mari Olofsson
SSG mail address: Eva-Mari.Olofsson@med.lu.se

The Scandinavian Sarcoma Group is a part of Lund University and follows the instructions/regulations for data protection for Lund University.

For more information please, follow this link https://www.lunduniversity.lu.se/about/contact-us/processing-of-personal-data-at-lund-university.

Closed protocols

ISG/SSG IV
Treatment protocol for high-risk Ewing´s family tumors.
Inclusion 1999-2009. Annals of Oncology 2012;23;2970-6. Since 2012 standard treatment care program.

ISG/SSG III
Treatment protocol for non metastatic Ewing´s family tumors.
Study inclusion begun 1999. Annals of Oncology 2011;22(5):1221-7. Since 2008 standard treatment care program.

ISG/SSG II
An Italian-Scandinavian treatment protocol for metastatic and pelvic osteosarcoma
1998-2002

ISG/SSG I
An Italian – Scandinavian treatment and research protocol for high-grade osteosarcoma of the extremities (localized disease and metastatic relapse)
1997-2000

SSG XVI
Centralized registration of patients with surgically treated skeletal metastases.
2002-2008

SSG XIV
Treatment research protocol for extremity localized high-grade osteosarcoma. (Age < 41 years).
2001-2005

SGG XXI – “PAGIST”
A Scandinavian Sarcoma Group treatment protocol for adult patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib. A non-comparative phase II multicenter study. Closed for inclusion October 2014.
The SSG XXI study protocol can be downloaded here. Latest CRF version and corresponding instructions can be downloaded from “Members only” and please note that this page is password protected and only available for SSG members.

SSG XVIII – A collaboration between the Scandinavian Sarcoma Group and the Sarcoma Group of the AIO, Germany
Short (12 months) versus long (36 months) adjuvant treatment with the tyrosine kinase inhibitor imatinib mesylate of operable gastrointestinal stromal tumors with a high risk for recurrence: A randomized phase III study. Closed for inclusion 2008. Results published.

SSG XIII
Treatment protocol for adult patients with high-risk soft tissue sarcoma of the extremities and trunk wall.
1998-2007

SSG XII
Metastasecetomy and chemotherapy for lungmetastases from STS. A randomized phase III study.
1996-2000

SSG XI
Palliative Oral Trofosfamide in the treatment of metastatic or locally advanced STS.
1994-1996

SSG X
Treatment of advanced STS with (VIG).
1991-1997

SSG IX
Combined modality therapy in EWS.
1990-1999

SSG VIII
The treatment of OS.
1990-1998

SSG VI
Combined modality therapy for OS
1987

SSG V
Treatment program for STS
1986

SSG IV
Combined modality therapy in EWS
1984-1990

SSG III
Radiotherapy in inoperable STS
1982

SSG II
Combination therapy in OS
1982-1990

SSG I
Adjuvant chemotherapy in STS
1981-1986

Latest updated February 1, 2016
EMO/KSH